Theta Biomedical Consulting & Development Co., Inc.
Records under this name other than the patents Theta Biomedical Consulting & Development Co., Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Back to Theta Biomedical Consulting & Development Co., Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,759,307 | Compositions for protection against superficial vasodilator flush syndrome, and methods of use Term ended Term ended Nov 5, 2025 · USPTO record | Term ended | Term ended Nov 5, 2025 | USPTO record |
| US 7,923,043 | Method for protecting humans against superficial vasodilator flush syndrome Lapsed on the fee record Ended Apr 12, 2023 · USPTO record | Lapsed on the fee record | Ended Apr 12, 2023 | USPTO record |
| US 6,689,748 | Method of treating mast cell activation-induced diseases with a proteoglycan Term ended Term ended May 3, 2020 · USPTO record | Term ended | Term ended May 3, 2020 | USPTO record |
| US 7,115,278 | Proteoglycan compositions for the treatment of cardiovascular inflammatory diseases Term ended Term ended Sep 2, 2019 · USPTO record | Term ended | Term ended Sep 2, 2019 | USPTO record |
| US 6,984,667 | Synergistic proteoglycan compositions for inflammatory conditions Term ended Term ended Oct 8, 2018 · USPTO record | Term ended | Term ended Oct 8, 2018 | USPTO record |
| US 6,645,482 | Proteoglycan compositions for treating arthritic inflammatory conditions Term ended Ended no later than May 22, 2018 · USPTO record | Term ended | Ended no later than May 22, 2018 | USPTO record |
| US 6,641,806 | Proteoglycan compositions for treating arthritic inflammatory conditions Term ended Ended no later than May 15, 2018 · USPTO record | Term ended | Ended no later than May 15, 2018 | USPTO record |
| US 6,635,625 | Proteoglycan compositions for treating prostate and bladder inflammatory conditions Term ended Ended no later than May 1, 2018 · USPTO record | Term ended | Ended no later than May 1, 2018 | USPTO record |
| US 6,624,148 | Proteoglycan compositions for treatment of cardiovascular inflammatory diseases Term ended Ended no later than Apr 8, 2018 · USPTO record | Term ended | Ended no later than Apr 8, 2018 | USPTO record |
| US 7,906,153 | Anti-inflammatory compositions for treating multiple sclerosis Term ended Ended no later than Apr 8, 2018 · USPTO record | Term ended | Ended no later than Apr 8, 2018 | USPTO record |